L. Tye
Pfizer (United States) · 54 works · 4,264 citations · h-index 19
Top works
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
- Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).
- Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
- Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.
- Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial
- Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
- Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC).
- Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
- Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study
- Variation in the pattern of metabolism of corticosteroids in fetal mouse tissues
- Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3
- Anastrozole: a new selective nonsteroidal aromatase inhibitor.
- Clinical Activity of Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Ros1 Gene Rearrangement
- A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)
- A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors
- Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer
- Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non–Small-Cell Lung Cancer: A Lead-In Study
- Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours
- Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study